Abstract Obesity is associated with blunted growth hormone (GH) secretion. In some individuals, hypothalamic-pituitary (HP) structural lesions may contribute to GH deficiency (GHD). We explored pituitary morphology in obese patients with suspected GHD and its association with cardiovascular risk factors, body composition, and cardiac morphology. One hundred and eighty-four adults obese patients with symptoms and signs of GHD (147 females and 37 males; mean age 46.31 ± 12.11 years), out of 906 consecutive white obese outpatients, were evaluated. The main measures were anthropometric data, blood pressure, lipid profile, glycemic parameters, pituitary hormones, and insulin-like growth factor-1 values, echocardiography, magnetic resonance imaging (MRI) of the HP region, body composition, and growth hormone-releasing hormone plus arginine test. Seventy patients had GHD (GH peak values \4.2 lg/mL). GHD patients showed significantly higher body mass index and fat mass, lower lumbar bone mineral density, increased left ventricular mass index, and epicardial fat thickness. The MRI of the HP region showed empty sella (ES) in 69 and normal pituitary in one of the 70 GHD patients; the 114 patients with normal GH response had ES (n = 62, 54 %), normal pituitary (n = 37, 32 %), microadenomas (n = 10, 8 %), and other pituitary abnormalities (n = 5, 4 %). ES was a significant independent predictor of GH secretory capacity as determined by multiple regression analysis. The close relationship between ES and GH secretory capacity points out to the possibility of the organic nature of GHD in a portion of obese individuals and opens a new scenario with regard to the potential of GH treatment on metabolic consequences of obesity.
Introduction
Obesity is a disease not always attributable to caloric imbalance, and various hypotheses are emerging to explain, at least in part, this growing epidemic [1] . The identification of conditions with causative roles in the development and maintenance of obesity and its comorbidities may have important clinical consequences.
Neuroendocrine dysfunctions are frequent in obese patients, and the common assumption is that they are functionally linked to increased adipose tissue with potential for delayed identification and investigation of HP diseases [2] .
The HP unit plays a central role in the maintenance of normal weight being directly involved in the control of energy homeostasis [3] . Either insufficiency or excess of anterior pituitary hormones have subtle effects on the accumulation of body fat severity of which depends on the mixture of changes, their degree, and duration. For example, Cushing's disease and excess of prolactin (PRL) may be associated with increased visceral fat; insufficiencies of anterior pituitary hormones affect the accumulation of adipose tissue [2] . A blunted growth hormone (GH) response is a frequent feature in obese individuals generally considered a functional result of obesity. However, obesity associates with profound changes in the structure of neurons and glia in the hypothalamus [4] and frequently shares with ES, idiopathic intracranial hypertension, and high intracranial pressure, all conditions with some degree of hypopituitarism [5, 6] . Collectively, abnormalities of the HP unit may be either a consequence of obesity or contribute to its development through a persistent organic failure. Therefore, in the obese patients with clinical characteristics of HP disease, an adequate functional and morphological assessment of HP unit is important to improve health outcomes [7] .
We evaluated HP MRI findings and cardiometabolic condition in obese individuals with clinical features of GHD. We report evidence that among the obese individuals, the coexistence of signs and symptoms of GHD other than obesity is frequent, and there is a marked association of ES with severe GHD. Furthermore, we found a significant relationship between the impaired GH secretion and the metabolic unhealthy phenotype in obese patients.
Materials and methods

Study design and participants
Nine hundred and six consecutive unselected white obese outpatients [676 females and 230 males; age range 11-64 years, mean ± SD 42.36 ± 13.09 years; BMI, expressed as weight (kg)/height (m 2 ) C30 kg/m 2 ], referred to our center for a first-level approach to the study of obesity and its comorbidities, were evaluated for a clinical, metabolic, and therapeutic assessment of obesity during the period of 2007-2013. All patients underwent neurological, ophthalmological, and baseline endocrine evaluations. 184 patients (37 males, 147 females, mean age 46.31 ± 12.11 years) with normal GH values and normal-to-low levels of IGF-1 for sex and age, in an appropriate clinical context [8] , namely those with signs and symptoms of GHD according to the Endocrine Society consensus guidelines [9] , underwent the GHRH plus arginine test (Fig. 1) . In particular, patients were selected if presenting IGF1 standard deviation score (SDS) between -1 and -3 and at least one symptom and one sign among these: lumbar T score \ -1; lean mass% \ 60 %; upper body fat deposition index (UFDI), the ratio between upper body fat (neck, arms, and trunk fat in kg) and lower body fat (legs fat in kg) [1.5; epicardial fat thickness (EFT) [ If adrenocorticotropic hormone (ACTH) deficiency was suspected, insulin tolerance test and cortisol daily curves were performed [9] .
No patient was treated with any drug until first line evaluation and stimulation tests were performed.
The study was approved by the biomedical research ethic committee of the University of Rome ''La Sapienza.'' This study is registered with ClinicalTrials.gov, number NCT02092779. All patients provided a written informed consent according to the Declaration of Helsinki.
Clinical measurements
Weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively. The waist circumference (WC) was measured just above the bony landmark of the iliac crest and expressed in centimeters. Hip circumference was measured around the pelvis at the point of maximal protrusion of the buttocks. Sitting systolic and diastolic blood pressure (SBP-DBP) was measured twice at 5-min intervals, and the average of two measurements was used for analysis.
Laboratory
Blood samples were collected after an overnight fast. Lipid status [total cholesterol (total-C), HDL cholesterol (HDL-C), and triglycerides (TG)] were determined using automated enzymatic method (Dade Behring SPA Milan). LDL cholesterol (LDL-C) was calculated using the Friedwald formula. The glucose determinations were performed using the hexokinase method (Aeroset Abbot Park, IL, USA), insulin was measured by radioimmuno-assay (Bayer 
Magnetic resonance imaging (MRI)
Pituitary gland MRI was performed using a 1.5 T scanner (Signa HDx, General Electric, Milwaukee, WI) with gadolinium contrast enhancement. The mid sagittal T1 image centered at the pituitary stalk was used to measure the central height, maximum length, and cross-sectional area of the gland. All measurements were obtained independently by two experienced physicians (A.P., A.L.) blinded to the clinical diagnosis with the aid of Codonics Software v4.0.1 [12] . Pituitary adenomas were distinguished by craniocaudal diameter taken in coronal sections into MA (smaller than 10 mm) and macroadenoma (larger than 10 mm). Patients with pituitary diameter B2 mm and more than 50 % filled with cerebrospinal fluid (CSF) were considered as total ES; patients with pituitary diameter C3 mm but B7 mm (the mean diameter of normal pituitary gland in adults) and less than 50 % filled with CSF were considered as partial ES [13] .
Echocardiography
Participants underwent high-resolution M-B mode transthoracic echocardiography using a 2.5 MHz Probe (Esaote MyLab40, Esaote Europe B.V., The Netherlands). Twodimensional echocardiography and standard M-mode measurements of left ventricle were performed as described [14, 15] . EF%, LVMI, SLVD, DLVD, and EFT were measured.
Dual-emission X-ray absorptiometry (DXA)
DXA measurement of body composition was performed using a DXA scan (QDR 4500 W, Hologic Inc., Bedford, MA, USA): lean mass, fat mass and bone mass were obtained as percent and as amount of fat (in grams) with a coefficient of variation \1 % for bone density and \1.5 % for fat mass [16] . Delimiters for regional analysis were determined by standard software (Hologic Inc., S/N 47168 VER. 11.2).
Statistical analysis
Data were analyzed by means of STATISTICA software, version 8.0 (Stat Soft, Inc., Tulsa, Oklahoma) and MedCalc Statistical Software version 13.0.2 (MedCalc Software bvba, Ostend, Belgium). Results are expressed as mean ± standard deviation (SD) unless otherwise specified. Differences between groups were analyzed using ANOVA for continuous variables. Linear correlation and multiple linear regression analyses were performed to identify associations between GH AUC and metabolic parameters and to identify the best predictor of GH peak and HOMA-IR. The cut-off threshold for peak GH after GHRH plus arginine was analyzed by receiver operating curve (ROC). For the purpose of ROC analysis, we assumed the patients with ES to be GHD according to our results and other studies [17] . All statistical assessments were considered significant if p \ 0.05.
Results
The demographic, anthropometric, and clinical characteristics of the 184 patients with at least one symptom and one objective sign possibly related to GHD disease [8, 9] stratified according to the GH peak values after GHRH plus arginine are shown in this group. The echocardiographic parameters related to the left ventricle were significantly altered in the GHD group, and lower EF% and higher EFT were present. Body composition by DXA revealed that in GHD patients, L2-L4 BMD and legs fat % were significantly lower, while the UFDI value was significantly higher compared with normal GHRH responders. Thus, the patients with GHD were heavier but not fatter and showed a particular distribution pattern of the adipose tissue characterized by a greater UFDI. The prevalence of metabolic syndrome (MetS) in the patients with GHD was higher compared with the control group (66.0 vs. 49 %, p \ 0.037). Linear correlation analyses to assess the relationships between AUC of GH response to GHRH plus arginine test and MetS diagnostic parameters, insulin and HOMA-IR showed a significant inverse association between preserved GH secretory capacity and all the parameters evaluated with the only exception of HDL-C that showed a significant direct relationship (Table 2) .
Age-and sex-adjusted multiple regression analyses for the association between GH peak response to GHRH plus arginine test and selected covariates related to body composition and to pituitary morphology possibly involved in the modulation of GH secretion (BMI, WC, UFDI, ES) revealed that ES and UFDI were independent predictors of GH secretory capacity (Table 3A) . Age-and sex-adjusted multiple regression analysis for the association of HOMA-IR with BMI, WC, and GH peak values is presented in Table 3B : GH peak was significantly associated with HOMA-IR. Furthermore, the odds ratio for GHD in ES patients was 63.44 (95 % CI 8.53-471.85; p = 0.0001).
ROC analysis (Fig. 2) to identify the GH cut-off value after GHRH plus arginine revealed that the cut-off with best pair of values for sensitivity and specificity (80.34 and 91.30 % respectively) was 5.73 lg/L.
Discussion
Adult GHD causes a clinical syndrome characterized by increased fat mass, adverse changes in lipid metabolism, carbohydrate metabolism, and cardiovascular function [18] [19] [20] . GH replacement therapy normalizes many of these signs and symptoms, but it is not approved in the absence of an appropriate clinical context, namely structural HP defects [21, 22] . The estimated incidence of adult-onset GHD is between 12 and 19 cases per million of the population [23] . However, the true incidence of adult-onset GHD remains unknown, owing in part to the lack of standardization of diagnostic criteria, and in part because not all patients at risk are routinely assessed for the diagnosis of GHD. Consensus statements indicate only adult patients with structural HP disease, surgery or irradiation in these areas, head trauma, or evidence of other pituitary hormone deficiencies are worth to be considered for evaluation for adult-acquired GHD [8, 9] . Moreover, screening in a clinical setting for GHD in obese patients is generally not accepted, mainly because of the negative influence of abdominal and visceral obesity on the secretion of GH [24] . However, a number of clinical questions still remain unanswered. Is the blunted GH response always functional (namely, correctable with weight reduction) or, in a proportion of obese patients, might GHD be organic? What is the clinical context for the evaluation of GHD in obese individuals? How much does GHD contribute to the cardiometabolic risk factors associated with obesity? Are there potential therapeutic consequences in terms of GH replacement therapies?
We found that among obese individuals with nonspecific signs and symptoms of GHD, ES is frequent, and the majority of them have a biochemically severe GHD, with a strong association between GHD and ES. Moreover, 23.18 % of ES GHD patients show multiple hormonal deficiencies. These data suggest ES as an associated organic cause in a proportion of formerly defined ''idiopathic'' GHD and open a new scenario on the actual prevalence of organic GHD in obesity. ES is seen in a range between 8 and 35 % of the general population [25] . Incidence and prevalence of hypopituitarism are estimated to be 4.2 per 100,000/years and 45.5 per 100,000, respectively [26] ; this means a prevalence of less than 0.05 %. These data are inconsistent with the reduced GH response to GHRH plus arginine found in 39.2-61 % of the patients with primary ES [5, 27] , which would predict a much higher prevalence of GHD. Thus, in obesity, ES is under diagnosed, and the expected prevalence of GHD could be underestimated. These findings indicate that complicated obesity may underlie GHD, and the clinical context to search for GHD in obese could be broader than was supposed. A rational consequence, worth being considered further, is that the quite variable improvement of GH secretion after weight loss might not occur when GHD and ES associate. Accordingly, persistence of ES despite a significant weight loss after bariatric surgery has been reported [28] , suggesting that in the presence of an organic basis for GHD, weight reduction, although beneficial, could not be curative.
Low endogenous GH secretion in the obese state associates with increased cardiometabolic risk factors [21] . Reduced GH secretion has been correlated with an adverse lipid and lipoprotein profile, increased abdominal adipose tissue mass, higher hs-CRP, and increased prevalence of diabetes [18] . However, since GH levels decline with aging and weight gain, and both elderly and obese individuals have a higher risk of developing cardiometabolic diseases independent of reduced GH [29] , it is difficult to determine whether changes in metabolic environment are specifically related to GHD or other concomitant conditions. In line with previous reports [18] , we found an inverse association between GH secretory capacity and the essential components of MetS, HbA-1c, and HOMA-IR values. Our findings extend the data available so far in the sense that the main parameter associated with insulin resistance is the GH peak independently from BMI and WC.
In our obese GHD patients, we found reduced lumbar BMD and lean body mass percentage and increased UFDI, a DXA-derived parameter strictly related to EFT that conveys information about the ratio between subcutaneous and visceral fat [17, 30] . All these conditions are known signs of GHD, virtually ascribable to the reduced action of GH on muscle, bone, and fat [21, 31] and offer a possible explanation for the coexistence of sarcopenia and osteopenia in a subset of obese patients [32] .
LVMI, SLVD, DLVD, and EFT were significantly increased in our GHD group, suggesting cardiac structural changes related to the impaired GH secretion capacity, possibly due to the increased intramyocellular fat deposition seen in individuals with blunted GH response [33, 34] . Some studies have disclosed beneficial effects of recombinant human GH treatment in patients with idiopathic dilated cardiomyopathy and ischemic cardiomyopathy [35, 36] ; exogenous GH is able to improve significantly cardiac function, with decreases in left ventricular end-diastolic and end-systolic dimensions [37] . Furthermore, EFT was significantly reduced after short-term GH replacement in patients with adult-onset GHD [38] . Our results do not confirm the decrease of cardiac mass seen in other studies involving GHD patients [39, 40] , although these data were taken from small populations of normal/overweight patients. The cardiac abnormalities we found might be a typical trait of organic GHD in obesity. Overall, these findings suggest that the GH secretory capacity is a major determinant of cardiac morphology and metabolic phenotype of the obese patients. Multiple regression analysis, performed to evaluate the influence of different covariates on GH secretion, shows that pituitary morphology and to lesser extent UFDI, but not BMI and WC, are related to GH peak values. These new findings suggest that the presence of ES might be the strongest determinant of reduced GH secretion in obese patients. Although novel, this is not unexpected since brain structural defects [9] , including ES syndrome and all the conditions compatible with acquired ES (traumatic brain injury, surgery, irradiation, infarction, inflammatory or infiltrative disorders), are recognized causes of organic GH deficiency. Interestingly, the GH peak response to GHRH plus arginine stimulus, more than BMI and WC, associates with HOMA-IR, suggesting that the GH secretory capacity is the major independent predictor of insulin resistance in the obese patients with symptoms and signs of GHD.
Obesity is the most important confounding factor for the diagnosis of nonfunctional GHD in adults. Nearly half of the patients with acquired HP disease are overweight or obese and normal GH secretory capacity is crucial for cardiometabolic health; thus, a proper GH peak cut-off value is important to identify organic GHD in obese patients. We suggest a cut-off value of 5.73 lg/L GH peak response to GHRH plus arginine for GHD that derives from a ROC analysis based on ES as positive condition for organic GHD [5, 17] . This cut-off differs from the currently accepted 4.2 lg/L GH diagnostic cut-off peak value in obese subjects. Based on the old and new cut-off, respectively 70 (38 %) and 98 (53 %) of the 184 patients with at least one symptom and one objective sign related to GHD were classified as having severe GHD. We think our cut-off value as appropriate, with ES being the covariate most strongly associated with the GH peak, in comparison with WC, BMI, IGF-1, impairment of lipid profile, reduced bone mineral density, and cardiac abnormalities. Furthermore, our cut-off is similar to the 5.5 lg/L value proposed in obese patients aged 26-65 years [41] , confirming that testing for GHD should be performed in patients with underlying HP disorders and strengthening the concept that ES should not be considered as merely an incidental finding, rather as a structural condition likely associated with GHD in obesity.
Clinical trials assessing the effects of GH treatment in obese patients showed consistent reductions in adipose tissue mass and in particular visceral depots [18] . Moreover, studies in patients with abdominal obesity demonstrate a marked effect of GH therapy on lipid and glucose homeostasis [18] . Therefore, administration of recombinant human GH has great potential to influence the onset and metabolic consequences of obesity, but the clinical use in obesity remains controversial [18, 21] -although, a recent study conducted on a large population of adult onset GHD patients, demonstrates that, in GH-treated patients, mortality decreases in total and due to malignancy compared with untreated patients, even after adjustment for all possible measured confounders [42] .
Conclusions
The coexistence of morphological alterations and signs/ symptoms of HP disease is frequent in obese patients. Our data, providing ES as an underlying organic cause for GHD in a portion of obese patients, portend new therapeutic outcomes. Whether GH replacement may improve obesity and the associated cardiometabolic risk factors in obese individuals with GHD and ES needs further studies.
Although the question remains whether ES and GHD are common co-travelers due to obesity and their cooccurrence reflects a causal effect of fat mass on ES pathogenesis and GHD, the high concurrence of ES and severe GHD in obese patients may have important consequences both for clinical screening and therapeutic approach, since the recovery of normal GH secretion because of GHD arising from ES is uncertain and the GH replacement in these patients might be appropriate.
There are some limitations in our study. This was a cross-sectional study, so we could not assess the causal relationship between the covariates evaluated and GHD. Second, the sex structures of the cohort is not balanced, but the interference of this factor with the results is unlikely since all the analytic data were corrected for age and sex.
